相关实验视频
Updated: Jul 5, 2026

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
协同的NIR-聚多巴胺纳米疗法用于穿越血脑屏障和帕金森病干预
Xueer Xia1,2, Jianbang Han3, Meiyin Lin4
1Medical Engineering &Engineering Medicine Innovation Center, Hangzhou International Innovation Institute, Beihang University No. 166, Shuanghongqiao Street, Yuhang District 311115 Hangzhou China sharon@buaa.edu.cn +86-13580346984.
RSC advances
|February 6, 2026
概括
研究人员开发了ZnO@PDA纳米复合材料,用于非侵入性帕金森病治疗. 这个平台为向治疗打开了血脑屏障,为神经退行性疾病提供了一种新方法.
科学领域:
- 纳米技术纳米技术
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
背景情况:
- 对于帕金森病的传统深脑刺激 (DBS) 是侵入性的.
- 对神经退行性疾病有需要的非侵入性治疗策略.
研究的目的:
- 为非侵入性神经疗法设计ZnO@polydopamine (ZnO@PDA) 纳米复合材料.
- 开发一个可逆血脑屏障 (BBB) 开放和向神经元刺激的平台.
主要方法:
- 制造 ZnO@PDA 纳米复合材料.
- 使用光热机制为BBB打开.
- 使用超声驱动电刺激进行神经元调节.
- 评估抗氧化和抗炎作用.
- 在帕金森病模型中进行体内研究.
主要成果:
- ZnO@PDA纳米复合材料通过光热效应实现了可逆的BBB打开.
- 纳米复合材料提供了向治疗和调制的神经元电路.
- 显示出强大的抗氧化活性,减少神经炎症,并减轻了α-synuclein聚合.
- 在体内研究表明,多巴胺能神经元功能的恢复和运动协调的改善.
结论:
- "透-积累-刺激"级联策略提供了一个变革性的方法.
- ZnO@PDA纳米复合材料为帕金森病提供了一个有前途的非侵入性治疗平台.
- 这种方法可以扩展到其他神经退行性疾病.
相关概念视频
Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

